Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

New capital, maturing pipelines, and a more global R&D mindset are pushing valuations higher, even as competition tightens.

Bristol Myers (BMY) delivered an impressive performance in the past month after being under pressure for quite some time. The ...

Pfizer Inc. has completed the previously announced global, ex-China, licensing agreement with 3SBio Inc., which grants Pfizer exclusive rights for the development, manufacturing and commercialization ...

Flatiron Health expands its international oncology research network, enhancing real-world data use to improve patient ...

Pfizer PFE is due to report second-quarter results on Aug. 5. All eyes will be on sales of Pfizer’s oncology drugs, which ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

The melanoma market is predicted to surge during the forecast period (2025–2034) owing to factors, as the increasing incidence of melanoma, the launc ...

The Global Bladder Cancer Market was valued at USD 4.4 Billion in 2024, and it is expected to reach USD 7.2 Billion by 2035, ...

It might be prudent to make a point of collecting a little more cash in the near future, and worry a little less about growth ...

The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who ...